These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 816365)

  • 1. [Plasma levels and biliary and urinary elimination of raubasine, dehydroergocristine and dihydroergotamine after venous administration in anesthetized dogs].
    Marzo A; Ghirardi P; Parenti MA; Merlo L; Marchetti G
    Boll Soc Ital Biol Sper; 1975 Jun; 51(11):684-6. PubMed ID: 816365
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of a combination of raubasine, dihydroergocristine and dihydroergotamine in dogs and human beings.
    Marzo A; Ghirardi P; Parenti MA; Merlo L; Marchetti G; Cavalca L; Omboni E; Pignataro T; Ligresti A
    Farmaco Prat; 1981 Apr; 36(4):173-97. PubMed ID: 6785104
    [No Abstract]   [Full Text] [Related]  

  • 3. [Observations during ambulatory therapy of functional and organic circulatory disorders with Defluina].
    Brüning G
    Med Welt; 1975 Sep; 26(38):1737-41. PubMed ID: 810634
    [No Abstract]   [Full Text] [Related]  

  • 4. Absorption and excretion of dihydroergocristine and dihydroergotamine in the dog.
    Marzo A; Ghirardi P; Merlo L; Marchetti G
    Farmaco Prat; 1978 Nov; 33(11):477-83. PubMed ID: 108136
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological aspects of dihydrogenated ergot alkaloids in experimental brain research.
    Meier-Ruge W; Emmenegger H; Enz A; Gygax P; Iwangoff P; Wiernsperger N
    Pharmacology; 1978; 16 Suppl 1():45-62. PubMed ID: 205890
    [No Abstract]   [Full Text] [Related]  

  • 6. Incorporation, after single and repeated application of radioactive labelled DH-ergot alkaloids in different organs of the cat, with special reference to the brain.
    Iwangoff P; Enz A; Meier-Ruge W
    Gerontology; 1978; 24 Suppl 1():126-38. PubMed ID: 412728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical treatment of peripheral arterial occlusive diseases].
    Schulte B
    Fortschr Med; 1976 Sep; 94(27):1500-4. PubMed ID: 823087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results.
    Bicalho B; Giolo JM; Lilla S; De Nucci G
    Biopharm Drug Dispos; 2008 Jan; 29(1):17-28. PubMed ID: 17941060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Action of defluine and its constituents on cerebral circulation in rabbits].
    Reuse-Blom S
    Boll Soc Ital Cardiol; 1975; 20(12):1689-92. PubMed ID: 825132
    [No Abstract]   [Full Text] [Related]  

  • 10. [Alpha-blocking activity of raubasine-dihydroergocristine combination in the demedullated rat].
    Roquebert J; Gomond P; Demichel P
    Ann Pharm Fr; 1983; 41(1):69-75. PubMed ID: 6137989
    [No Abstract]   [Full Text] [Related]  

  • 11. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
    Müller-Schweinitzer E; Rosenthaler J
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):686-93. PubMed ID: 2442535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cerebrovascular processes and their reactions to pharmacotherapy by means of ultrasonic methods.
    Klein K; Klein M; Klein P
    Z Alternsforsch; 1985; 40(6):369-74. PubMed ID: 2934900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroergotamine binding to rat brain membranes.
    Closse A; Hauser D
    Life Sci; 1976 Dec; 19(12):1851-63. PubMed ID: 12440
    [No Abstract]   [Full Text] [Related]  

  • 14. [Drugs with first-pass elimination. Verapamil and dihydroergotamine alkaloids].
    Rietbrock N; Woodcock BG
    Internist (Berl); 1982 Nov; 23(11):610-5. PubMed ID: 6759451
    [No Abstract]   [Full Text] [Related]  

  • 15. [Quantitative rheographic study of the effects of a new drug combination: raubasine/dihydroergocristine].
    Henriet M; Jacquy J; Noel G
    Brux Med; 1974 Dec; 54(12):743-5. PubMed ID: 4215548
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparative plethysmographic study of the venoconstrictor effect of dihydroergotamine and dihydroergotoxine on the deep veins of the calf in healthy subjects and patients suffering from varicosis.
    Barthel W; Grossmann K
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):458-64. PubMed ID: 7141753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of dihydroergotamine and hydergine on the lesser circulation in man].
    HALMAGYI D; IVANYI J; FELKAI B; ZSOTER T; TENYI M; SZUCS Z
    Magy Belorv Arch Ideggyogy Szle; 1952 Dec; 5(4):160-3. PubMed ID: 13131993
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of raubasine and dihydroergocristine on an age-related deficit in passive avoidance learning in rats.
    Chopin P; Briley M
    J Pharm Pharmacol; 1990 May; 42(5):375-6. PubMed ID: 1976794
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of acute and subacute treatment with ergot drugs on the GABA system in specific brain regions.
    Pericić D
    J Pharm Pharmacol; 1981 Oct; 33(10):655-9. PubMed ID: 6117619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of ergoloid mesylates liquid capsule.
    Schran HF
    Clin Ther; 1985; 8(1):71-5. PubMed ID: 3833371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.